Kymera Therapeutics has entered a significant agreement with Gilead Sciences to jointly develop oral molecular glue degraders targeting CDK2 for solid tumors, including breast cancer. The deal includes up to $85 million in upfront and option exercise fees and potential milestone payments up to $750 million. Concurrently, Kymera is advancing an oral IRAK4 degrader, KT-485, into clinical testing with Sanofi after Sanofi decided not to pursue their previous IRAK4 candidate. These collaborations validate Kymera's position in the emerging protein degradation drug modality and may accelerate the development of innovative cancer therapies.